Navigation Links
Shire to Present New Scientific Data on ADHD Treatment Portfolio at,APA Annual Meeting

nsion and agitation; glaucoma; tics, diagnosis or a family history of Tourette's syndrome; seizures; or during or within 14 days after treatment with monoamine oxidase inhibitors (MAOIs).

Sudden death has been reported in association with CNS stimulant treatment at usual doses in children and adolescents with structural cardiac abnormalities or other serious heart problems. Sudden deaths, stroke, and myocardial infarction have been reported in adults taking stimulant drugs at usual doses in ADHD. Physicians should take a careful patient history, including family history, and physical exam, to assess the presence of cardiac disease. Patients who report symptoms of cardiac disease such as exertional chest pain and unexplained syncope should be promptly evaluated. Use with caution in patients whose underlying medical condition might be affected by increases in blood pressure or heart rate.

New psychosis, mania, aggression, growth suppression, and visual disturbances have been associated with the use of stimulants. Use with caution in patients with a history of: psychosis; EEG abnormalities; bipolar disorder; depression. Growth and hematologic monitoring is advised during prolonged treatment. Patients should avoid applying external heat to the DAYTRANA patch. Skin irritation or contact sensitization may occur.

DAYTRANA should be given cautiously to patients with a history of drug dependence and alcoholism. Chronic abuse can lead to marked tolerance and psychological dependence. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use, since severe depression may occur. Withdrawal following chronic therapeutic use may unmask symptoms of the underlying disorder.

Common adverse events reported by patients who received DAYTRANA in clinical trials were decreased appetite, insomnia, nausea, vomiting, decreased weight, tics, affect lability, and anorexia, consistent with
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
(Date:8/27/2015)... , Aug. 27, 2015  The Academy ... Food and Drug Administration,s (FDA,s) draft guidance and ... products and biosimilars, to bear a nonproprietary name ... has been seeking a decision from the FDA ... diverse health care stakeholders urging the agency to ...
(Date:8/27/2015)... , Aug. 27, 2015 ieCrowd™ ... in the commercial development of the company,s supplemental ... Smart Oxygen device, being developed by ieCrowd,s subsidiary ... a patient,s changing demand for oxygen based on ... 510 (k) submission for the Smart Oxygen device ...
(Date:8/27/2015)... N.J. , Aug. 27, 2015   Women Grow , ... cannabis industry, is partnering with the Cannabis World Congress ... to produce 15 business-focused educational sessions. CWCBExpo in ... Los Angeles Convention Center in ... event on the West Coast for the marijuana industry. ...
Breaking Medicine Technology:AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 2Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 3Smart Oxygen Solutions' Supplemental Oxygen Delivery Device Achieves FDA Regulatory Pathway Milestone 4Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 2Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 3Cannabis World Congress in Los Angeles Boasts Women Grow Sponsored Education 4
... subsequently,respond, have substantially more treatment costs, and ... COLORADO SPRINGS, Colo., April 03, 2007 /PRNewswire-FirstCall/,-- ... Congress on,Schizophrenia Research (ICOSR) suggest that antipsychotic ... thought, and,challenge the current schizophrenia treatment paradigm ...
... Amyloid Plaque Formation, ANNAPOLIS, Md., April 03, ... company specializing in the development,and commercialization of ... today that new data from its,recombinant butyrylcholinesterase ... 8th International Conference on,Alzheimer's and Parkinson's Diseases ...
Cached Medicine Technology:New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 2New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 3New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 4New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 5New Data Show Early Non-Response to Antipsychotic Treatment May Be,Strong Predictor of Subsequent Non-Response for People with,Schizophrenia 6PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 2PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 3PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 4PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 5PharmAthene's Recombinant Butyrylcholinesterase (rBChE) Program the,Subject of Promising New Alzheimer's Research 6
(Date:8/29/2015)... , ... August 29, 2015 , ... ... include treating the localized area with stretching, soft tissue manipulation. Platelet rich plasma ... position have shown through research to improve treatment outcomes. This localized treatment ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... management, Decatur County Memorial Hospital recently transitioned management companies to partner with Wound ... Management for their outpatient wound center. , Transitioning wound care management providers ...
(Date:8/28/2015)... , ... August 28, 2015 , ... An article ... local pizza maker Paul LaRocco has gone through to open a pizzeria in Westchester. ... permitting process tends to take several months, but the current process, having already gone ...
(Date:8/28/2015)... ... 28, 2015 , ... As reported by Medical Daily on August 22 ... results that last for two years, the longest of any cellulite reduction system currently ... for a long-lasting, effective solution for their cellulite, according to Dr. Robert Weiss, director ...
(Date:8/28/2015)... ... 28, 2015 , ... Saint Petersburg, FL —Pocket Protein™, a ... carbs, sugar, gluten, lactose or caffeine in a convenient 2 oz. pouch that ... Editor’s Choice Awards. , Five consumer packaged goods (CPG) products were selected by ...
Breaking Medicine News(10 mins):Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Article on Building Approval Process for LA Business Highlights the Need for a Bridge Between Businesses and City Officials, says Fire Protection Group Inc. 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 2Health News:Maryland Dermatologists Discuss Non-Invasive Cellulite Reduction System Cellfina Receiving 2-Year FDA Clearance 3Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 2Health News:Pocket Protein™ Named 2015 CPG Editor’s Choice Award Finalist by Informa’s SupplySide 3
... Digirad Corporation,(Nasdaq: DRAD ), a leading provider ... offices, hospitals and imaging centers, today,announced that it ... Program,for San Diego. The prestigious honor recognizes the ... in the,San Diego area based on percentage revenue ...
... NEW YORK, Oct. 15 Highlands Acquisition Corp.,(Amex: ... for,the Company,s initial public offering have exercised in ... public offering. As,a result, the Company sold an ... share of common stock and one warrant to ...
... SEOUL, South Korea, Oct. 15 Dong-A PharmTech Co. ... contract with,Otechestvennye Lekarstva OJSC, to market in Russia Dong-A,s ... the brand name of,Zydena. Under the terms of ... pharmaceutical firms, will pay both upfront fees and,running royalty ...
... Ended 2007, BANGOR, Maine, Oct. 15 Nyer Medical ... results for its,fiscal year ended June 30, 2007. Revenues increased ... compared to $63,596,975 as reported for,the same period ended June ... $.02 basic net earnings per common share for the year ...
... Findings could bring new treatment options for patients, ... -- Surgery patients may one day find nicotine ... prescription pad, researchers say. , Nicotine patches and ... following surgery, according to two studies presented at ...
... FORT WORTH, Texas, Oct. 15 DSS Research asked ... around PFFS sales,practices in their June Senior Trax(TM) survey. ... Medicare eligibles. Overall, 13.3% said they,had heard or read ... past two months. This figure ranged from a high ...
Cached Medicine News:Health News:Digirad Corporation Named to Deloitte Technology Fast 50 2Health News:Digirad Corporation Named to Deloitte Technology Fast 50 3Health News:Highlands Acquisition Corp. Announces Exercise of Over-Allotment Option 2Health News:Dong-A PharmTech Signs Licensing Deal With Otechestvennye to Market Zydena in Russia 2Health News:Nyer Medical Group, Inc. Reports EPS of $.02 on Record Revenues of $69.9 Million for Fiscal Year Ended 2007 2Health News:Nyer Medical Group, Inc. Reports EPS of $.02 on Record Revenues of $69.9 Million for Fiscal Year Ended 2007 3Health News:Nyer Medical Group, Inc. Reports EPS of $.02 on Record Revenues of $69.9 Million for Fiscal Year Ended 2007 4Health News:Nicotine, Chili Peppers Offer Post-Surgery Pain Relief 2Health News:Nicotine, Chili Peppers Offer Post-Surgery Pain Relief 3
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Clinical micro clamps by Acland. Matte finish. It provides impressive security in use, both against slippage and against leakage due to controlled closing force and working grip surface....
Extremely fine straight....
Curved delicate 5 mm blades....
Medicine Products: